Progentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.
Location: United States, Massachusetts, Watertown
Total raised: $65M
Investors 3
| Date | Name | Website |
| 10.07.2026 | Alta Partn... | altapartne... |
| 20.05.2025 | Mission Bi... | missionbio... |
| 19.05.2025 | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.05.2024 | Series A | $65M | - |
Mentions in press and media 5
| Date | Title | Description |
| 24.05.2024 | The Week’s 10 Biggest Funding Rounds: Scale AI’s Massive $1B Deal Leads Slower Week | 9 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 22.05.2024 | Progentos Therapeutics Launches With $65M | WATERTOWN, MA, Progentos Therapeutics hAS announced its launch and the closing of a $65 million series A round. >> Click here for more funding data on Progentos Therapeutics >> To export Progentos Therapeutics funding data to P... |
| 21.05.2024 | Forbion leads $65 million Series A Financing of Progentos Therapeutics | • Forbion led the Series A financing to support the development of Progentos’ lead program in multiple sclerosis along with additional pipeline programs • Progentos Therapeutics is developing novel small molecules to induce de-novo remyelin... |
| 20.05.2024 | Progentos Therapeutics Closes $65M Series A Financing | Progentos Therapeutics, a Watertown, MA-based biotech company addressing the need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, closed a $65m series A funding round. Th... |
| - | Progentos Therapeutics | “Progentos Therapeutics is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.” |